Retatrutide news

All news on Retatrutide (also known as LY-3437943, Retatrutide, and BI 456906): plants, production capacities, investments and involved companies.

23 July 2026

Lilly's retatrutide shows large weight and A1C reductions in Phase 3 TRIUMPH‑2 and TRIUMPH‑3

First‑in‑class triple agonist delivered large 80‑week weight losses and meaningful A1C and cardiometabolic improvements in difficult‑to‑treat obesity populations.
16 July 2026

Boehringer Ingelheim: BI 3034701 triple GLP‑1/GIP/NPY2 agonist enters Phase II

Phase II starts for a potential first‑in‑class triple GLP‑1/GIP/NPY2 receptor agonist targeting weight, satiety and central hunger signalling; study includes dose finding and safety/efficacy evaluation.
21 May 2026

Lilly’s retatrutide achieves up to 30% weight loss in Phase 3 TRIUMPH-1

Phase 3 TRIUMPH-1: three doses met endpoints at 80 weeks with dose-related, substantial weight loss. 104-week extension in BMI≥35 showed further loss; cardiometabolic markers improved; GI AEs common.
6 May 2026

Eli Lilly commits $4.5B to Indiana manufacturing, opens first genetic‑medicine facility

Buildout now totals $21B in Indiana since 2020; upgrades at Lebanon API to produce Foundayo, Zepbound/Mounjaro and retatrutide; project to scale API capacity and boost regional jobs and GDP.
30 January 2026

Lilly to Build $3.5B Manufacturing Facility in Pennsylvania

The new facility will create 2,800 jobs, produce weight-loss medicines, and boost the local economy with advanced technologies and partnerships in education and workforce development.

Who will be producing Retatrutide in the future?

Find out with chemXplore Alpha

Learn more